top of page
Our
Platforms
MiniBinders: A novel approach to extracellular protein degradation
-
We have identified a novel modality that is well-suited for targeted protein degradation.
-
We have identified and characterized E3 ligases expressed on cancer cells, opening up the door to new targets and indications.

CargoTek: Re-doseable AAV therapies
-
Demonstrated re-dosing of AAV in mice with CargoTek.
-
Entered into a strategic research collaboration with AAV company.

bottom of page